{"schema_version":"secwatch.filing_event.v1","accession":"0001846253-24-000086","form_type":"8-K","ticker":"OABI","cik":"0001846253","company_name":"OmniAb, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.014369+00:00","generated_at":"2026-05-30T02:12:27.488290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"OmniAb Q3 2024 revenue $4.2M (down 24% YoY), net loss $16.4M; partner pipeline grows","bullets":["Q3 2024 revenue $4.2M (down 24% YoY); net loss $16.4M ($0.16/sh) vs $15.7M ($0.16/sh) in Q3 2023.","Cash $59.4M at Sept 30; sold 2.0M shares via ATM for $8.5M in Q3, plus $2.9M post-quarter.","FY 2024 total opex expected slightly below 2023; FY 2024 cash balance guided at $50-60M.","Entered three new platform licenses in Q3 (92Bio, MSKCC, Queen Mary London) plus Incyte after quarter.","Partner events: Immunovant IMVT-1402 IND cleared in RA; Genmab to start Ph3 for acasunlimab; CStone sugemalimab UK approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001846253-24-000086","json":"https://secwatch.observer/filing/0001846253-24-000086.json","markdown":"https://secwatch.observer/filing/0001846253-24-000086.md","text":"https://secwatch.observer/filing/0001846253-24-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1846253/000184625324000086/0001846253-24-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1846253/000184625324000086/oabi-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:12:27.488290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}